Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Samsung Enters Oncology as Trastuzumab Accepted For EU Review

Executive Summary

Samsung Bioepis's trastuzumab has become the South Korean company’s fifth biosimilar candidate to be filed for approval in Europe and also marks its planned entry into the oncology sector in the region.


Related Content

2016 Review: Mixed Bag Of Hope, Setbacks For Korean Pharma
Biocon Confident As First Biosimilars Seen Hitting Europe In Early 2018
Celltrion's Biosimilar Strategy Includes Simultaneous EMA/FDA Reviews
Samsung Seeks Third Anti-TNF Biosimilar Launch In Europe


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst